Virax Biolabs Group Analyst Price Targets - Benzinga

Virax Biolabs Group Ltd

VRAXNASDAQ

Trade with Public

Trade with Public

$2.63

0.0652.54%

At close: Sep 4, 5:00 PM EST

$2.54

-0.085-3.24%

After Hours: Sep 4, 7:23 AM EST

Overview News EventsPrice TargetsFinancials Sentiment Compare Stock Report

Virax Biolabs Group Analyst Price Targets

Wall Street analyst price targets and consensus rating for Virax Biolabs Group (VRAX).

Price Target Range — 2 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$1Upside to Avg. PT-60.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jan 9, 2026	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$3→$1
Mar 31, 2025	HC Wainwright & Co.	Yi Chen	Initiate	Buy	$3

Analyst Ratings News

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

Vandana Singh

PRO
HC Wainwright & Co. Initiates Coverage On Virax Biolabs Group with Buy Rating, Announces Price Target of $3

HC Wainwright & Co. analyst Yi Chen initiates coverage on Virax Biolabs Group (NASDAQ:VRAX) with a Buy rating and announces Price Target of $3.

Benzinga Newsdesk